KANGFANG

About us

Position:HOME > About us > Management Team

201606171466150432.jpg Michelle Xia (President/CEO, Ph.D.)

Dr. Michelle Xia has over 20 years of experience in biopharmaceutical industry and academic research. Prior to founding Akeso Biopharma, she was Senior Vice President at Crown Bioscience, in charge of the Biologics Business Unit and Pfizer-Crown Asian Cancer Research Center. Prior to joining Crown Bioscience, Dr. Xia worked at PDL BioPharma (acquired by Abbott Labs) in the San Francisco Bay Area, one of the pioneer therapeutic antibody technology and drug development company, where she served as a core member in CMC project teams overseeing drug substance and product process development/manufacturing, technology transfer and FDA registration/IND enabling process. Prior to that, Dr. Xia worked at the CMC Process Development Department of Bayer in Berkeley. Her responsibilities there included building the Pathogen Safety facility at Bayer and managing viral safety evaluation/purification process validation for manufacturing biological products. Dr. Xia began her biopharmaceutical career at AXY Pharmaceuticals, which was acquired by Celera Genomics in 2001. During the six-year service with AXY/Celera, she played both scientific and managerial roles in drug discovery programs from target validation through IND enabling.

Dr. Xia received her B. S. in Biochemistry from Zhongshan University in China and earned her Ph. D. in Molecular Biology and Microbiology from University of Newcastle in U.K. She did her postdoctoral research at University of Glasgow in U.K. and cancer immune therapy research at University of Louisville Medical School in the U.S.

.................................................................................................................................................................................................................

201606171466150436.jpg Baiyong Li (VP/CSO, Ph.D.)
Dr. Baiyong Li is an expert in immunology and antibody drug discovery. Prior to founding Akeso Biopharma, he was a senior scientific leader at Pfizer since 1999 and specialized in new drug discovery for the treatment of immune-related diseases and cancer. He led and participated in multiple projects on discovery, pre-clinical and clinical studies of new antibody drugs. Dr. Li was appointed head of Pfizer Crown drug discovery group and led the formation of the Pfizer – Crown Asian Cancer Research Center in 2010. He displayed instrumental leadership in advancing multiple Drug discovery projects at the joint venture, pioneering antibody drug discovery research in China.
Dr. Li obtained his B. S. in Biochemistry from Nankai university in 1991 and his Ph. D. in molecular and cell biology from 
Pennsylvania State University in 1996. He conducted postdoctoral research at Dr. Richard Flavell's lab at Yale University Schoolof Medicine.

..................................................................................................................................................................................................................

201606171466150439.jpg Max Wang (VP/CBO, Ph.D.)

Dr. Max Wang has over 20 years of industrial and academic experience in structure biology and drug discovery. Prior to founding Akeso Biopharma, he was executive director at Crown Biosciences, responsible for establishing and managing protein and structural biology group. He also started a structure based antibody engineering platform there, carrying out antibody humanization and affinity maturation. Prior to joining Crown Bioscience, Dr. Wang worked at Ardea Biosciences (acquired by AstraZeneca), where he made major contributions to several kinase inhibitor candidates through x-ray crystallography and structure based drug design. Before that, Dr. Wang was a group leader at Trimeris, Inc. (acquired by Alexion), leader in peptide based HIV fusion inhibitors. He had crystallized and determined more than 30 complex structures, which led to new generations of fusion inhibitors. Before that, Dr. Wang worked at New Century Pharmaceuticals, Inc., focusing on albumin based drug discovery and other blood related protein therapeutics. He led a group of scientists and solved more than 200 complex structures of albumin with leading drugs on the market.
Dr. Wang obtained his B. S. in Physics from University of Science and Technology of China in 1991, and his Ph. D. in Structural and Computational Biology and Molecular Biophysics from Baylor College of Medicine in 1998. 

...............................................................................................................................................................................................................................................

 

201606171466150442.jpg Peng Zhang (VP/COO, Ph.D.)

Dr. Peng Zhang is an expert in protein biochemistry and analytical science. Prior to founding Akeso Biopharma, he was senior director of the protein group at Crown Bioscience, in charge of protein and antibody reagent provision services to major pharmaceutical and biotechnology companies. During three years of time, he led the group to successfully deliver more than 100 projects to JnJ, Pfizer, Teva, Lundbeck, GSK, and many other clients with very high satisfaction. Before joining Crown Bioscience, he was a scientific leader at PDL Biopharma, making contributions to analytical data packages for several FDA filing. 
Dr. Zhang obtained his Bachelor and Master degree in Chemistry from Shandong University in 1998 and Ph. D. in Biochemistry from University of Kentucky in 2006. 

...............................................................................................................................................................................................................................................